Opeolu Adeoye1, Heidi Sucharew2, Jane Khoury2, Thomas Tomsick2, Pooja Khatri2, Yuko Palesch2, Pamela A Schmit2, Arthur M Pancioli2, Joseph P Broderick2. 1. From the University of Cincinnati Neuroscience Institute, OH (O.A., P.K., P.A.S., A.M.P., J.P.B.); Departments of Emergency Medicine (O.A., P.A.S., A.M.P.), Neurosurgery (O.A.), Radiology (T.T.), and Neurology (P.K., J.P.B.), University of Cincinnati, OH; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, OH (H.S., J.K.); and Division of Biostatistics, Medical University of South Carolina, Charleston, SC (Y.P.). Opeolu.Adeoye@uc.edu. 2. From the University of Cincinnati Neuroscience Institute, OH (O.A., P.K., P.A.S., A.M.P., J.P.B.); Departments of Emergency Medicine (O.A., P.A.S., A.M.P.), Neurosurgery (O.A.), Radiology (T.T.), and Neurology (P.K., J.P.B.), University of Cincinnati, OH; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, OH (H.S., J.K.); and Division of Biostatistics, Medical University of South Carolina, Charleston, SC (Y.P.).
Abstract
BACKGROUND AND PURPOSE: The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial demonstrated safety of recombinant tissue-type plasminogen activator (r-tPA) plus eptifibatide in acute ischemic stroke (AIS). CLEAR-ER randomized AIS patients (5:1) to 0.6 mg/kg r-tPA plus eptifibatide versus standard r-tPA (0.9 mg/kg). Interventional Management of Stroke III randomized AIS patients to r-tPA plus endovascular therapy versus standard r-tPA. Albumin in Acute Stroke Part 2 randomized patients to albumin±r-tPA versus saline±r-tPA. Our aim was to compare outcomes in CLEAR-ER combinationarm patients to propensity score-matched r-tPA only subjects in Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III. METHODS: The primary outcome was 90-day severity-adjusted modified Rankin score (mRS) dichotomization based on baseline National Institutes of Health Stroke Scale. Secondary outcomes were 90-day mRS dichotomization as excellent (mRS, 0-1); mRS dichotomization as favorable (mRS, 0-2); and nonparametric analysis of the ordinal mRS. RESULTS:Eighty-five combination arm CLEAR-ER subjects were matched with 169 Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III trials' r-tPA only patients (controls). Median age in CLEAR-ER and control subjects was 68years; median National Institutes of Health Stroke Scale in the CLEAR-ER subjects was 11 and in control subjects 12. At 90 days, CLEAR-ER subjects had a nonsignificantly greater proportion of patients with favorable outcomes (45% versus 36%; unadjusted relative risks, 1.24; 95% confidence intervals, 0.91-1.69; P=0.18). Secondary outcomes were 52% versus 34% excellent outcomes (relative risks, 1.51; 95% confidence intervals, 1.13-2.02; P=0.007); 60% versus 53% favorable outcome (relative risks, 1.13; 95% confidence intervals, 0.90-1.41; P=0.31); and ordinal Cochran-Mantel-Haenszel P=0.10. CONCLUSION:r-tPA plus eptifibatide showed a favorable direction of effect that was consistent across multiple approaches for AIS outcome evaluation. A phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes is warranted.
RCT Entities:
BACKGROUND AND PURPOSE: The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial demonstrated safety of recombinant tissue-type plasminogen activator (r-tPA) plus eptifibatide in acute ischemic stroke (AIS). CLEAR-ER randomized AIS patients (5:1) to 0.6 mg/kg r-tPA plus eptifibatide versus standard r-tPA (0.9 mg/kg). Interventional Management of Stroke III randomized AIS patients to r-tPA plus endovascular therapy versus standard r-tPA. Albumin in Acute Stroke Part 2 randomized patients to albumin±r-tPA versus saline±r-tPA. Our aim was to compare outcomes in CLEAR-ER combination arm patients to propensity score-matched r-tPA only subjects in Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III. METHODS: The primary outcome was 90-day severity-adjusted modified Rankin score (mRS) dichotomization based on baseline National Institutes of Health Stroke Scale. Secondary outcomes were 90-day mRS dichotomization as excellent (mRS, 0-1); mRS dichotomization as favorable (mRS, 0-2); and nonparametric analysis of the ordinal mRS. RESULTS: Eighty-five combination arm CLEAR-ER subjects were matched with 169 Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III trials' r-tPA only patients (controls). Median age in CLEAR-ER and control subjects was 68years; median National Institutes of Health Stroke Scale in the CLEAR-ER subjects was 11 and in control subjects 12. At 90 days, CLEAR-ER subjects had a nonsignificantly greater proportion of patients with favorable outcomes (45% versus 36%; unadjusted relative risks, 1.24; 95% confidence intervals, 0.91-1.69; P=0.18). Secondary outcomes were 52% versus 34% excellent outcomes (relative risks, 1.51; 95% confidence intervals, 1.13-2.02; P=0.007); 60% versus 53% favorable outcome (relative risks, 1.13; 95% confidence intervals, 0.90-1.41; P=0.31); and ordinal Cochran-Mantel-Haenszel P=0.10. CONCLUSION:r-tPA plus eptifibatide showed a favorable direction of effect that was consistent across multiple approaches for AIS outcome evaluation. A phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes is warranted.
Authors: Philip M W Bath; Kennedy R Lees; Peter D Schellinger; Hernan Altman; Martin Bland; Cheryl Hogg; George Howard; Jeffrey L Saver Journal: Stroke Date: 2012-03-15 Impact factor: 7.914
Authors: Oh Young Bang; Jeffrey L Saver; Suk Jae Kim; Gyeong-Moon Kim; Chin-Sang Chung; Bruce Ovbiagele; Kwang Ho Lee; David S Liebeskind Journal: Stroke Date: 2011-01-13 Impact factor: 7.914
Authors: Arthur M Pancioli; Opeolu Adeoye; Pamela A Schmit; Jane Khoury; Steven R Levine; Thomas A Tomsick; Heidi Sucharew; Claudette E Brooks; Todd J Crocco; Laurie Gutmann; Thomas M Hemmen; Scott E Kasner; Dawn Kleindorfer; William A Knight; Sharyl Martini; James S McKinney; William J Meurer; Brett C Meyer; Alexander Schneider; Phillip A Scott; Sidney Starkman; Steven Warach; Joseph P Broderick Journal: Stroke Date: 2013-07-25 Impact factor: 7.914
Authors: Myron D Ginsberg; Yuko Y Palesch; Michael D Hill; Renee H Martin; Claudia S Moy; William G Barsan; Bonnie D Waldman; Diego Tamariz; Karla J Ryckborst Journal: Lancet Neurol Date: 2013-09-27 Impact factor: 44.182
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Maciej Bladowski; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Anna Sawicz-Bladowska; Adrian Doroszko Journal: Oxid Med Cell Longev Date: 2020-08-28 Impact factor: 6.543
Authors: Paula Muñoz Venturelli; Jason P Appleton; Craig S Anderson; Philip M Bath Journal: Curr Neurol Neurosci Rep Date: 2018-09-18 Impact factor: 5.081
Authors: Maren Ranhoff Hov; Erik Zakariassen; Thomas Lindner; Terje Nome; Kristi G Bache; Jo Røislien; Jostein Gleditsch; Volker Solyga; David Russell; Christian G Lund Journal: J Neuroimaging Date: 2017-07-27 Impact factor: 2.486